齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
12期
1775-1776
,共2页
孟鲁司特%酮替芬%支气管哮喘
孟魯司特%酮替芬%支氣管哮喘
맹로사특%동체분%지기관효천
Montelukast%Ketotifen%Bronchial asthma
目的:分析孟鲁司特及酮替芬治疗支气管哮喘的临床价值。方法选取我院2013年8月至2014年8月门诊诊治的支气管哮喘患者90例,随机分为观察组和对照组。对两组患者均进行止咳和平喘的常规治疗,在进行此常规治疗的基础上,给予观察组患者孟鲁司特钠咀嚼片10 mg,令其每晚顿服;给予对照组患者酮替芬片1 mg,令其口服2次/d。对患者进行3个月治疗后,观察两组患者的临床治疗效果,并记录两组患者治疗中出现的不良反应。结果两组患者治疗后第一秒呼气容积与呼气峰值流速较治疗前均有明显提高,观察组对支气管哮喘的治疗效果显著优于对照组,其不良反应也比对照组少。结论孟鲁斯特治疗支气管哮喘的疗效优于酮替芬,值得在临床中推广使用。
目的:分析孟魯司特及酮替芬治療支氣管哮喘的臨床價值。方法選取我院2013年8月至2014年8月門診診治的支氣管哮喘患者90例,隨機分為觀察組和對照組。對兩組患者均進行止咳和平喘的常規治療,在進行此常規治療的基礎上,給予觀察組患者孟魯司特鈉咀嚼片10 mg,令其每晚頓服;給予對照組患者酮替芬片1 mg,令其口服2次/d。對患者進行3箇月治療後,觀察兩組患者的臨床治療效果,併記錄兩組患者治療中齣現的不良反應。結果兩組患者治療後第一秒呼氣容積與呼氣峰值流速較治療前均有明顯提高,觀察組對支氣管哮喘的治療效果顯著優于對照組,其不良反應也比對照組少。結論孟魯斯特治療支氣管哮喘的療效優于酮替芬,值得在臨床中推廣使用。
목적:분석맹로사특급동체분치료지기관효천적림상개치。방법선취아원2013년8월지2014년8월문진진치적지기관효천환자90례,수궤분위관찰조화대조조。대량조환자균진행지해화평천적상규치료,재진행차상규치료적기출상,급여관찰조환자맹로사특납저작편10 mg,령기매만돈복;급여대조조환자동체분편1 mg,령기구복2차/d。대환자진행3개월치료후,관찰량조환자적림상치료효과,병기록량조환자치료중출현적불량반응。결과량조환자치료후제일초호기용적여호기봉치류속교치료전균유명현제고,관찰조대지기관효천적치료효과현저우우대조조,기불량반응야비대조조소。결론맹로사특치료지기관효천적료효우우동체분,치득재림상중추엄사용。
Objective To analyze the clinical value of montelukast and ketotifen treatment on bronchial asthma.Methods 90 patients with bronchial asthma in our hospital from 2013 August to 2014 selected August outpatient treatment patients, randomly divided into observation group and control group.The conventional treatment of two groups of patients were cough and asthma, based on the conventional treatment, the patients in observation group were given the Meng Lu division special sodium chewable tablets 10mg, its nightly meal served;the patients in the control group were given ketotifen tablets 1mg, its oral 2/d.3 months after treatment of the patient, to observe the clinical therapeutic effect of two groups were recorded, and the adverse reactions of two groups of patients in the treatment.Results Two groups of patients treated expiratory volume and peak expiratory flow rate were increased significantly compared with those before treatment, the observation group on bronchial asthma treatment effect is significantly better than the control group, the adverse reaction is less than the control group.Conclusions The curative effect of montelukast in the treatment of bronchial asthma is better than ketotifen, it is worth promoting in clinical use.